Part D Plans Bracing For Wegovy; Strict Prior Authorizations To Prevent Obesity Use Are Likely

Despite worries about potential costs of inadvertently covering Wegovy for obesity because of patient (and physician) gaming, Novo’s new CV claim expected to garner wide formulary adoption. Since coverage for weight loss drugs is still prohibited in Medicare, CMS may issue guidance.